Advertisement

Topics

Lectus Therapeutics Limited Company Profile

14:38 EST 16th December 2018 | BioPortfolio

Lectus Therapeutics Limited is a UK-based drug discovery and development company, specialising in the discovery and development of best- and first-in-class ion channel therapeutics for urinary bladder disorders, pain and angina.
Lectus, which began operations in the summer of 2003, exploits the power of its proprietary functional proteomics platform, LEPTICS® (Leveraged Enabling Proteomics Technology for Ion Channel Screening), and builds on its knowledge of ion channels and protein-protein interactions, to identify and develop next-generation ion channel modulators that offer desirable clinical profiles with commensurate economic advantages.

Location

PO Box 2299
Bristol
BS99 5YG
United Kingdom

Contact

Phone: 44 (0)117 928 8973
Fax: 44 (0)117 925 2659
Email: roland.kozlowski@lectusth.com


News Articles [718 Associated News Articles listed on BioPortfolio]

Almac Discovery Appoints Biology VP

Dr. Xavier Jacq has held positions at Sanofi-Synthelabo, Hybrigenics, Lectus Therapeutics, and AstraZeneca

Almac Discovery Names Biology VP

Dr. Xavier Jacq has held positions at Sanofi-Synthelabo, Hybrigenics, Lectus Therapeutics, and AstraZeneca

Quotient Limited Announces Details of Investor Day

JERSEY, Channel Islands, July 16, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced details of its investor day held at the NASDAQ he...

Glythera Limited Announces Corporate Name Change and Rebranding to Iksuda Therapeutics

New identity reflects transition in corporate focus, from technology licensing to drug development, for previously untreatable cancers Newcastle, UK, 10th September, 2018: Glythera Limited (Gly...

Quotient Limited to Host Investor Day on July 16, 2018

JERSEY, Channel Islands, June 18, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that it will host an Investor Day on Monday, July ...

Quotient Limited Announces Completion of Senior Secured Notes Offering

JERSEY, Channel Islands, July 02, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), has completed the offering of up to $120.0 million ...

Quotient Limited Announces Pricing of Underwritten Offering of Ordinary Shares

JERSEY, Channel Islands, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the pricing of its previously annou...

Quotient Limited Announces Initial MosaiQ™ SDS Verification and Validation Data

JERSEY, Channel Islands, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported positive Verification and Validation...

PubMed Articles [462 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Eyes on New Product Development.

Clinical Trials [164 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1368 Associated Companies listed on BioPortfolio]

Lectus Therapeutics Limited

Lectus Therapeutics Limited is a UK-based drug discovery and development company, specialising in the discovery and development of best- and first-in-class ion channel therapeutics for urinary bladder...

Immunocore Limited

Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located ...

Millendo Therapeutics, Inc.

Millendo Therapeutics is focused on developing a portfolio of disease-modifying treatments for endocrine diseases caused by hormone dysregulation. Our product candidates seek to i...

Circadian Technologies Limited

Circadian Technologies Limited is an emerging leader in the field of angiogenesis-based treatments for cancer. Focusing on a class of drug targets called Vascular Endothelial Growth Factors (VEGFs),...

Microsulis Medical Limited

Founded in 1997, Microsulis Medical Limited is a UK-based medical device company that exploits specialist intellectual property in medical microwave design to create therapeutic d...

More Information about "Lectus Therapeutics Limited" on BioPortfolio

We have published hundreds of Lectus Therapeutics Limited news stories on BioPortfolio along with dozens of Lectus Therapeutics Limited Clinical Trials and PubMed Articles about Lectus Therapeutics Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Lectus Therapeutics Limited Companies in our database. You can also find out about relevant Lectus Therapeutics Limited Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Urology
Benign Prostatic Hyperplasia (BPH) Erectile Dysfunction Urology Urology is the branch of medicine concerned with the urinary tract and diseases that affect it. Examples include urethritis, urethrostenosis and incontinence. Urology is a su...


Corporate Database Quicklinks



Searches Linking to this Company Record